EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol

A. Petrillo; L. Oudijk; R. Sundar; C. Daumer; J. Casas; D. D'Haese; M. Mauer; N. van Grieken; E. C. Smyth; M. Moehler

doi:10.1016/j.esmogo.2024.100071

EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol

A. Petrillo^*
, L. Oudijk
, R. Sundar
, C. Daumer
, J. Casas
, D. D'Haese
, M. Mauer
, N. van Grieken
, E. C. Smyth
, M. Moehler

^*Corresponding author for this work

Ospedale del Mare
Erasmus University Rotterdam
National University of Singapore
National University Cancer Institute
European Organisation for Research and Treatment of Cancer Data Center
Oxford University Hospitals NHS Foundation Trust
Johannes Gutenberg University Mainz

Research output: Contribution to journal › Article › Academic › peer-review

14 Downloads (Pure)

Abstract

The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among patients with gastro-oesophageal cancer (GC). Yet, there are no comprehensive global studies comparing the various methods and antibodies utilized for assessing PD-L1 positivity in GC. The ASPIRE study, led by the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Group (EORTC GITCG) and the National University Health System, Singapore, seeks to standardize the assessment of PD-L1 expression in GC. By comparing various PD-L1 scoring systems and assays, the study aims to simplify and harmonize the quantification and qualification of PD-L1 expression. Ultimately, this effort aims to facilitate the translation of endpoints in companion diagnostic settings. Here, we report the protocol of the study.

Original language	English
Article number	100071
Journal	ESMO Gastrointestinal Oncology
Volume	5
DOIs	https://doi.org/10.1016/j.esmogo.2024.100071
Publication status	Published - 1 Sept 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.esmogo.2024.100071

Eortc-stomach-cancer-pd-l1-biomarker-european-initiative.pdfFinal published version, 677 KBLicence: CC BY

Cite this

@article{d4b61f2700954ae5b06e1e20842e85ac,

title = "EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol",

abstract = "The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among patients with gastro-oesophageal cancer (GC). Yet, there are no comprehensive global studies comparing the various methods and antibodies utilized for assessing PD-L1 positivity in GC. The ASPIRE study, led by the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Group (EORTC GITCG) and the National University Health System, Singapore, seeks to standardize the assessment of PD-L1 expression in GC. By comparing various PD-L1 scoring systems and assays, the study aims to simplify and harmonize the quantification and qualification of PD-L1 expression. Ultimately, this effort aims to facilitate the translation of endpoints in companion diagnostic settings. Here, we report the protocol of the study.",

author = "A. Petrillo and L. Oudijk and R. Sundar and C. Daumer and J. Casas and D. D'Haese and M. Mauer and \{van Grieken\}, N. and Smyth, \{E. C.\} and M. Moehler",

year = "2024",

month = sep,

day = "1",

doi = "10.1016/j.esmogo.2024.100071",

language = "English",

volume = "5",

journal = "ESMO Gastrointestinal Oncology",

issn = "2949-8198",

}

TY - JOUR

T1 - EORTC stomach cancer PD-L1 biomarker European initiative

T2 - the ASPIRE study protocol

AU - Petrillo, A.

AU - Oudijk, L.

AU - Sundar, R.

AU - Daumer, C.

AU - Casas, J.

AU - D'Haese, D.

AU - Mauer, M.

AU - van Grieken, N.

AU - Smyth, E. C.

AU - Moehler, M.

PY - 2024/9/1

Y1 - 2024/9/1

N2 - The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among patients with gastro-oesophageal cancer (GC). Yet, there are no comprehensive global studies comparing the various methods and antibodies utilized for assessing PD-L1 positivity in GC. The ASPIRE study, led by the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Group (EORTC GITCG) and the National University Health System, Singapore, seeks to standardize the assessment of PD-L1 expression in GC. By comparing various PD-L1 scoring systems and assays, the study aims to simplify and harmonize the quantification and qualification of PD-L1 expression. Ultimately, this effort aims to facilitate the translation of endpoints in companion diagnostic settings. Here, we report the protocol of the study.

AB - The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among patients with gastro-oesophageal cancer (GC). Yet, there are no comprehensive global studies comparing the various methods and antibodies utilized for assessing PD-L1 positivity in GC. The ASPIRE study, led by the European Organisation for Research and Treatment of Cancer Gastrointestinal Tract Group (EORTC GITCG) and the National University Health System, Singapore, seeks to standardize the assessment of PD-L1 expression in GC. By comparing various PD-L1 scoring systems and assays, the study aims to simplify and harmonize the quantification and qualification of PD-L1 expression. Ultimately, this effort aims to facilitate the translation of endpoints in companion diagnostic settings. Here, we report the protocol of the study.

UR - https://www.scopus.com/pages/publications/105021651938

U2 - 10.1016/j.esmogo.2024.100071

DO - 10.1016/j.esmogo.2024.100071

M3 - Article

SN - 2949-8198

VL - 5

JO - ESMO Gastrointestinal Oncology

JF - ESMO Gastrointestinal Oncology

M1 - 100071

ER -

EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this